Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $45,871 | $37,958 | $20,042 | $7,680 |
| % Growth | 20.8% | 89.4% | 161% | – |
| Cost of Goods Sold | $6,378 | $1,279 | $885 | $0 |
| Gross Profit | $39,493 | $36,679 | $19,157 | $7,680 |
| % Margin | 86.1% | 96.6% | 95.6% | 100% |
| R&D Expenses | $56,280 | $62,227 | $61,636 | $65,529 |
| G&A Expenses | $0 | $43,805 | $41,031 | $37,690 |
| SG&A Expenses | $44,917 | $43,805 | $41,031 | $37,690 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4,278 | $0 | $247 | $826 |
| Operating Expenses | $96,919 | $106,032 | $102,914 | $104,045 |
| Operating Income | -$57,426 | -$69,353 | -$83,757 | -$96,365 |
| % Margin | -125.2% | -182.7% | -417.9% | -1,254.8% |
| Other Income/Exp. Net | -$3,289 | -$2,494 | -$1,089 | $2,196 |
| Pre-Tax Income | -$60,715 | -$71,847 | -$84,846 | -$94,169 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$60,715 | -$71,847 | -$84,846 | -$94,169 |
| % Margin | -132.4% | -189.3% | -423.3% | -1,226.2% |
| EPS | -0.7 | -0.83 | -0.99 | -1.1 |
| % Growth | 15.7% | 16.2% | 10% | – |
| EPS Diluted | -0.7 | -0.83 | -0.99 | -1.1 |
| Weighted Avg Shares Out | 86,621 | 86,337 | 85,622 | 85,791 |
| Weighted Avg Shares Out Dil | 86,621 | 86,337 | 85,622 | 85,791 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $5,950 | $7,183 | $7,108 |
| Interest Expense | $3,014 | $7,858 | $8,051 | $4,806 |
| Depreciation & Amortization | $1 | $0 | $9,138 | $0 |
| EBITDA | -$57,700 | -$63,989 | -$83,757 | -$89,363 |
| % Margin | -125.8% | -168.6% | -417.9% | -1,163.6% |